
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2018

IMPRIMIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-35814
(Commission
File Number)

45-0567010
(IRS Employer
Identification No.)

12264 El Camino Real, Suite 350
San Diego, CA
(Address of principal executive offices)

92130
(Zip Code)

Registrant's telephone number, including area code: **(858) 704-4040**

N/A

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-
-

Item 8.01. Other Information.

On November 12, 2018, Eton Pharmaceuticals, Inc. (“Eton”) issued a press release (the “Eton PR”) reporting the pricing of its initial public offering of three million six hundred thousand (3,600,000) shares of its common stock at a public price of \$6.00 a share. The Eton PR also stated that Eton’s common stock has been approved for listing on the Nasdaq Global Market and is expected to begin trading under the ticker symbol “ETON” on November 13, 2018. The proposed offering is expected to close on November 15, 2018, subject to customary closing conditions. Imprimis Pharmaceuticals, Inc. owns three million five hundred thousand (3,500,000) shares of Eton common stock.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Eton securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

The foregoing is only a brief description of the Eton PR, does not purport to be a complete description of the Eton PR and is qualified in its entirety by reference to the full text of the document, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01.**Financial Statements and Exhibits****(d) Exhibits**

99.1 [Eton Pharmaceuticals, Inc. Press Release dated November 12, 2018](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Imprimis Pharmaceuticals, Inc.

Date: November 13, 2018

By: /s/ Andrew R. Boll

Name: Andrew R. Boll

Title: Chief Financial Officer

Eton Pharmaceuticals Announces Pricing of Initial Public Offering

DEER PARK, Ill., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced the pricing of its initial public offering of 3,600,000 shares of its common stock at a public offering price of \$6.00 per share. All of the shares are being offered by Eton. In addition, Eton has granted the underwriter a 45-day option to purchase an additional 540,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Eton, are expected to be approximately \$21.6 million, excluding any proceeds from the exercise of the underwriter's option to purchase additional shares. Eton's common stock has been approved for listing on the Nasdaq Global Market and is expected to begin trading under the ticker symbol "ETON" on November 13, 2018. The proposed offering is expected to close on November 15, 2018, subject to customary closing conditions.

National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NASDAQ: NHLD), is acting as the sole underwriter for the offering. The Liquid Venture Partners group at National Securities Corporation was responsible for sourcing and executing the offering.

The Securities and Exchange Commission declared a registration statement relating to these securities effective on November 9, 2018. Interested parties may obtain copies of the final prospectus relating to this offering from:

National Securities Corporation
200 Vesey Street, 25th Floor
New York, NY 10281
Attn: Marguerite O'Brien
Telephone: (212) 417-8164
Email: prospectusrequest@nationalsecurities.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Eton Pharmaceuticals, Inc

Eton Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on developing and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway. Eton has a diversified pipeline of high-value product candidates in various stages of development.

Company Contact:

David Krempa
dkrempa@etonpharma.com
847-805-1077
